| dbo:abstract
|
- ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600. The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008. (en)
|
| dbo:foundedBy
| |
| dbo:foundingYear
| |
| dbo:industry
| |
| dbo:location
| |
| dbo:netIncome
| |
| dbo:numberOfEmployees
|
- 232 (xsd:nonNegativeInteger)
|
| dbo:operatingIncome
| |
| dbo:product
| |
| dbo:revenue
| |
| dbo:thumbnail
| |
| dbo:type
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 9602 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:defunct
| |
| dbp:foundation
| |
| dbp:founder
|
- Claude H. Nash (en)
- Guy D. Diana (en)
- Johanna A. Griffin (en)
- Marc S. Collett (en)
- Mark A. McKinlay (en)
|
| dbp:homepage
| |
| dbp:industry
| |
| dbp:keyPeople
| |
| dbp:location
| |
| dbp:logo
| |
| dbp:name
|
- ViroPharma Incorporated (en)
|
| dbp:netIncome
| |
| dbp:numEmployees
| |
| dbp:operatingIncome
| |
| dbp:products
| |
| dbp:revenue
| |
| dbp:tradedAs
| |
| dbp:type
|
- Public NASDAQ Biotechnology Index (en)
|
| dbp:wikiPageUsesTemplate
| |
| dbp:wordnet_type
| |
| dct:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:homepage
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
|
- ViroPharma Incorporated (en)
|
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
